Articles in Category: More News
A publication from 2023 researching Fabry disease, pharm-analyt involved
Comparison of efficacy between subcutaneous and intravenous application of moss-aGal in the mouse model of Fabry disease, co-author Daniel Mascher, Gb3 and lyso Gb-3
Download PDFRefining the Overall Strategy after 38 Years

pharm-analyt Working on its Key Account and Overall Strategy: A process having started on 3 April 2024 with an external consultant will be concluded by 30 November 2024
Meet our Founder @ World Orphan Drug Congress in Boston

World Orphan Drug Congress in the USA: 23.04.2024-25.04.2024
Meet one of our GMP QPs @ Analytica in München

Analytica in Germany: 09.04.2024-12.04.2024